The ISSCR joined with the Ad Hoc Group for Medical Research and 349 member organizations representing patients, clinicians, scientists, educators, academic institutions, research organizations, and industry, in a letter thanking President-elect Joseph R. Biden, Jr. for his steadfast support for science. The letter states, "As the oldest coalition advocating for the federal investment in the National Institutes of Health (NIH) and biomedical, bioengineering, behavioral, and social science research, we are grateful that you support increased and sustainable funding growth for the NIH as part of $300 billion in new research and development investments in your Build Back Better plan."

The ISSCR shared comments with the European Medicines Agency (EMA) related to its Network Strategy 2025. This included support for the crucial role of EMA and national regulators in overseeing the development of new products and offer a few recommendations to ensure that new products are proven safe and effective before being marketed to patients.

The ISSCR met 11 April with the European Parliament’s Committee on Industry, Research and Energy to advocate for investments in basic research in the European Union’s 9th Framework Programme for Research and Innovation. ISSCR members Pete Coffey and Michele De Luca, along with ISSCR Policy Director Eric Anthony, described the need for continued investments in basic research to improve understanding of human physiology and develop new approaches to treat disease.

In a letter to the European Commission today, the ISSCR encourages the EU to spur innovation by supporting basic research and programs that foster cooperation among fundamental research endeavors across Europe. "Sustained investments in fundamental research will stimulate innovation-led growth for years to come," according to the letter, signed by ISSCR president Hans Clevers.